trending Market Intelligence /marketintelligence/en/news-insights/trending/ufjxjktvxuce8wlyyjc5iw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

HVIVO vaccine reduces influenza symptoms in midstage trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

HVIVO vaccine reduces influenza symptoms in midstage trial

HVIVO PLC's experimental influenza vaccine FLU-v helped in reducing infection rates and severity and duration of symptoms in a midstage trial.

FLU-v, also known as FLU-v 003, is being developed to provide immunity against multiple influenza strains without the need for annual immunization.

The phase 2b study, which included 176 patients aged 18 to 60, met its main goal of improving the T and B cell immune responses of the patients against influenza infection after 42 days and 180 days after a single vaccination. T and B cells are a type of white blood cells in the immune system that help protect the body against infections.

Additionally, a single dose of the vaccine was shown to induce the strongest immunological response rates and this group experienced a 60% reduction in influenza confirmed infections and an 83% reduction in the number of influenza confirmed cases with severe symptoms compared to placebo.

The London-based company said FLU-v is now ready to be studied in a phase 3 trial.

Imutex Ltd., hVIVO's 49% joint venture with PepTcell Ltd., trading as SEEK Group, is responsible for the development of FLU-v.